342 related articles for article (PubMed ID: 36754139)
1. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
2. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
[TBL] [Abstract][Full Text] [Related]
3. Relationship between increased serum neurofilament light chain and glial fibrillary acidic protein levels with non-motor symptoms in patients with Parkinson's disease.
Yin P; Niu X; Guan C; Zhang Z; Liu Y; Li J; Cui G; Zan K; Xu C
Psychogeriatrics; 2024 Mar; 24(2):415-425. PubMed ID: 38339819
[TBL] [Abstract][Full Text] [Related]
4. Association between serum neurofilament light chain levels and sleep disorders in patients with Parkinson's disease.
Li Y; Li F; Liu X; Zu J; Zhang W; Zhou S; Zhu J; Zhang T; Cui G; Xu C
Neurosci Lett; 2023 Aug; 812():137394. PubMed ID: 37437874
[TBL] [Abstract][Full Text] [Related]
5. Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study.
Lin J; Ou R; Li C; Hou Y; Zhang L; Wei Q; Pang D; Liu K; Jiang Q; Yang T; Xiao Y; Zhao B; Chen X; Song W; Yang J; Wu Y; Shang H
BMC Med; 2023 Nov; 21(1):420. PubMed ID: 37932720
[TBL] [Abstract][Full Text] [Related]
6. Utility of serum neurofilament light chain and glial fibrillary acidic protein as diagnostic biomarkers of freezing of gait in Parkinson's disease.
Liu X; Liu X; Liu Y; Yang B; Li Y; Li F; Qian K; Zu J; Zhang W; Zhou S; Zhang T; Liu J; Cui G; Xu C
Brain Res; 2024 Jan; 1822():148660. PubMed ID: 37924925
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
[TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
[TBL] [Abstract][Full Text] [Related]
9. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
Aamodt WW; Waligorska T; Shen J; Tropea TF; Siderowf A; Weintraub D; Grossman M; Irwin D; Wolk DA; Xie SX; Trojanowski JQ; Shaw LM; Chen-Plotkin AS
Mov Disord; 2021 Dec; 36(12):2945-2950. PubMed ID: 34480363
[TBL] [Abstract][Full Text] [Related]
10. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
11. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
[TBL] [Abstract][Full Text] [Related]
12. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression.
Hviid CVB; Benros ME; Krogh J; Nordentoft M; Christensen SH
J Affect Disord; 2023 Oct; 338():341-348. PubMed ID: 37336248
[TBL] [Abstract][Full Text] [Related]
13. Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study.
Pötter-Nerger M; Dutke J; Lezius S; Buhmann C; Schulz R; Gerloff C; Kuhle J; Choe CU
J Neural Transm (Vienna); 2022 Mar; 129(3):295-300. PubMed ID: 35072765
[TBL] [Abstract][Full Text] [Related]
14. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
[TBL] [Abstract][Full Text] [Related]
15. Combination of plasma amyloid beta
Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
[TBL] [Abstract][Full Text] [Related]
16. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
[TBL] [Abstract][Full Text] [Related]
17. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
[TBL] [Abstract][Full Text] [Related]
18. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
19. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
[TBL] [Abstract][Full Text] [Related]
20. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients.
Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M
Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
